Core Insights - Hoth Therapeutics is adopting Lantern Pharma's PredictBBB.ai platform, which boasts a 94% accuracy in predicting blood-brain barrier permeability, positioning the company at the forefront of AI-driven drug development [1][2][3] Company Overview - Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments aimed at improving patient quality of life [5] - The company emphasizes a patient-centric approach and collaborates with scientists, clinicians, and key opinion leaders to explore therapeutics with significant potential [5] Strategic Impact - The integration of PredictBBB.ai allows Hoth to enhance precision in candidate selection, reduce development risks, and potentially create faster regulatory pathways for its drug pipeline [4] - The ability to cross the blood-brain barrier is identified as a critical success factor for drug candidates, and the AI tool is expected to streamline this process [4] Leadership Statements - Hoth's CEO, Robb Knie, highlighted the commitment to utilizing disruptive technologies like AI to drive efficiency and unlock new opportunities for patients and shareholders [5] - Lantern Pharma's CEO, Panna Sharma, expressed enthusiasm for the collaboration, noting the potential of PredictBBB.ai to accelerate CNS drug development [3]

Company Overview - Lantern Pharma is leveraging its AI platform, RADR®, to transform cancer drug discovery and development, aiming to reduce costs and accelerate timelines[5, 6] - The company has raised approximately $100 million in total capital since 2019[5] - RADR® can predict and stratify real-world patients for clinical trials with 88% accuracy[6] - Lantern has 12 disclosed and collaborative lead drug programs[11] Drug Development Programs - LP-300, targeting Non-Small Cell Lung Cancer (NSCLC) in never smokers, represents a $4+ billion global annual market potential and is currently in Phase 2 clinical trials[23, 24] - Initial Phase 2 trial data for LP-300 showed an 86% clinical benefit rate in the safety lead-in cohort[38, 43] - LP-184, targeting advanced solid tumors with DDR deficiencies, has a $14+ billion annual US market potential and is in Phase 1 clinical trials[54, 55] - LP-284, targeting B-cell Non-Hodgkin's Lymphomas (NHL), represents a $4 billion annual global market potential and is also in Phase 1 clinical trials[88, 89] AI Platform and Collaborations - Lantern's RADR® platform incorporates over 100 billion data points from 130K+ patient records and advanced ML algorithms[13] - The company has strategic collaborations with academic, research institutions, and biopharma companies to accelerate timelines and gain unique real-world insights[19, 20, 21]